SOHO 2019 | What are the novel prognostic factors for the treatment of patients with CLL?
At SOHO 2019, we spoke to Dr Alessandra Ferrajoli about novel prognostic factors and how they are used for the treatment of patients with chronic lymphocytic...
Prevalence of BTK and PLCG2 mutations in a CLL cohort still on ibrutinib after three years
Anne Quinquenel conducted a study to investigate patients from the FILO study, who were still on ibrutinib after three years.
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox every month